We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

547 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 178 increasing their positions, 207 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 50

36% more call options, than puts

Call options by funds: $193M | Put options by funds: $141M

12% more capital invested

Capital invested by funds: $16.1B → $18B (+$1.96B)

5% more funds holding

Funds holding: 519 → 547 (+28)

2.79% more ownership

Funds ownership: 96.45% → 99.24% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

14% less repeat investments, than reductions

Existing positions increased: 178 | Existing positions reduced: 207

Holders
547
Holders Change
+28
Holders Change %
+5.39%
% of All Funds
7.97%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
85
Increased
178
Reduced
207
Closed
50
Calls
$193M
Puts
$141M
Net Calls
+$51.4M
Net Calls Change
-$924K

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$421M
2
EIM
Elliott Investment Management
Florida
+$265M
3
Deutsche Bank
Deutsche Bank
Germany
+$177M
4
Morgan Stanley
Morgan Stanley
New York
+$99M
5
Millennium Management
Millennium Management
New York
+$80M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$337M
2
Nomura Holdings
Nomura Holdings
Japan
-$62.6M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$56.1M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$44.7M
5
PHS
PFM Health Sciences
California
-$44.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
VanEck Associates
126
VanEck Associates
New York
$12.9M -$1.86M -20,975 -14%
EAM
127
EULAV Asset Management
Florida
$12.5M -$180K -2,036 -2%
DZ Bank
128
DZ Bank
Germany
$12.5M -$1.9M -21,421 -14%
CCM
129
Cutter Capital Management
New York
$12.5M +$11.5M +129,906 New
SVCM
130
Saturn V Capital Management
Texas
$11.5M +$841K +9,503 +9%
Macquarie Group
131
Macquarie Group
Australia
$11.4M -$1.03M -11,653 -9%
WCMNY
132
Westchester Capital Management (New York)
New York
$11.4M +$10.5M +118,400 New
State of Wisconsin Investment Board
133
State of Wisconsin Investment Board
Wisconsin
$11.2M +$420K +4,745 +4%
ACP
134
Altitude Crest Partners
Connecticut
$11M +$10.1M +114,042 New
State of New Jersey Common Pension Fund D
135
State of New Jersey Common Pension Fund D
New Jersey
$10.5M – – –
Treasurer of the State of North Carolina
136
Treasurer of the State of North Carolina
North Carolina
$10M +$535K +6,050 +6%
TAM
137
Tocqueville Asset Management
New York
$9.9M -$2.36M -26,665 -21%
GAM
138
Groupama Asset Management
France
$9.72M +$8.91M +100,753 New
DA
139
DSC Advisors
Illinois
$9.64M – – –
Victory Capital Management
140
Victory Capital Management
Texas
$9.6M -$1.83M -20,646 -17%
Rafferty Asset Management
141
Rafferty Asset Management
New York
$9.31M -$188K -2,126 -2%
Canada Life
142
Canada Life
Manitoba, Canada
$9.28M -$693K -7,831 -7%
VOYA Investment Management
143
VOYA Investment Management
Georgia
$8.94M +$412K +4,662 +5%
UBS Group
144
UBS Group
Switzerland
$8.91M -$13.5M -152,805 -62%
AllianceBernstein
145
AllianceBernstein
Tennessee
$8.72M +$156K +1,762 +2%
Handelsbanken Fonder
146
Handelsbanken Fonder
Sweden
$8.68M -$151K -1,705 -2%
SGA
147
Sector Gamma AS
Norway
$8.32M -$867K -9,801 -10%
MSV
148
MN Services Vermogensbeheer
Netherlands
$8.3M -$292K -3,300 -4%
Ohio Public Employees Retirement System (OPERS)
149
Ohio Public Employees Retirement System (OPERS)
Ohio
$8.27M +$63.9K +722 +0.8%
ACM
150
Atika Capital Management
New York
$8.2M +$7.52M +85,000 New
4 5
6
7 8

BMRN Hedge Fund Activity: Q4 2023 in Review

547 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2023, worth a combined $18B — up 12% from $16.1B a quarter earlier.

Buyers outnumbered sellers: 85 funds opened new BMRN positions and 50 closed out — a net gain of 35 holders — while 178 added to existing stakes and 207 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $421M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $337M sold.

  • 547 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2023, up from 519 in Q3 2023.
  • Funds reported $18B of BioMarin Pharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
  • 85 funds opened new BioMarin Pharmaceuticals positions in Q4 2023 and 50 closed out, a net change of +35 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2023 was Capital Research Global Investors, an estimated $421M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2023 was Baker Bros. Advisors, an estimated $337M sold.

Based on aggregated 13F filings for Q4 2023.